657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIL-6R blockadeEfficacy of immune checkpoint inhibitorsMedian timeAdverse eventsIL-6RAnti-programmed cell death-1 antibodyImmune checkpoint inhibitor infusionsImmune mediated adverse eventsOverall tumor response ratePre-existing autoimmune diseaseInterleukin-6Interleukin-6 receptor blockadeClinical Disease Activity IndexICI-treated patientsTumor response rateMedian CRP levelsProspective clinical trialMinimal disease activityRelated adverse eventsDisease activity indexIrAE managementCheckpoint inhibitorsInterleukin-6 receptorMedian dose